ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

ONXX Onyx Pharmaceuticals, Inc. (MM)

124.70
0.00 (0.00%)
Pre Market
Last Updated: 01:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type
Onyx Pharmaceuticals, Inc. (MM) NASDAQ:ONXX NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 124.70 0 01:00:00

Onyx Pharmaceuticals to Present at the Goldman Sachs 30th Annual Global Healthcare Conference

02/06/2009 9:10pm

PR Newswire (US)


Onyx Pharmaceuticals, Inc. (MM) (NASDAQ:ONXX)
Historical Stock Chart


From Jul 2019 to Jul 2024

Click Here for more Onyx Pharmaceuticals, Inc. (MM) Charts.
EMERYVILLE, Calif., June 2 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) today announced that it will present at the Goldman Sachs 30th Annual Global Healthcare Conference on Tuesday, June 9, at 10:10 a.m. Eastern Time. Interested parties may access a live webcast of the presentation on our website at: http://www.onyx-pharm.com/wt/page/event_calendar It is recommended that listeners log on 15 minutes early in order to register and download any necessary software. For those unable to participate during the live webcast, a recorded replay of the presentation will be available one hour following the conclusion of the presentation through July 9, 2009. Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer. The company, in collaboration with Bayer HealthCare Pharmaceuticals, Inc., is developing and marketing Nexavar(R), a small molecule drug. Nexavar is currently approved for the treatment of liver cancer and advanced kidney cancer. Additionally, Nexavar is being investigated in several ongoing trials in a variety of tumor types. For more information about Onyx, visit the company's website at http://www.onyx-pharm.com/. Nexavar(R) (sorafenib) tablets is a registered trademark of Bayer Pharmaceuticals Corporation. DATASOURCE: Onyx Pharmaceuticals, Inc. CONTACT: Alex Santos, +1-510-597-6504, for Onyx Pharmaceuticals, Inc. Web Site: http://www.onyx-pharm.com/

Copyright

1 Year Onyx Pharmaceuticals, Inc. (MM) Chart

1 Year Onyx Pharmaceuticals, Inc. (MM) Chart

1 Month Onyx Pharmaceuticals, Inc. (MM) Chart

1 Month Onyx Pharmaceuticals, Inc. (MM) Chart